Compare Mounjaro, Wegovy, Saxenda and oral options by dosing frequency, monthly cost, planned total and country pricing.
For price and budget comparison only. No diagnosis, prescribing or prediction of individual treatment response. A clinician decides medicine, dose, initiation, maintenance and discontinuation.
15.0 kg / 15.0% target loss · 12 month budget comparison
Cost to actually reach your target cannot be predicted. Amounts below budget a fixed quote over your selected horizon, without prescribing titration, maintenance or stopping.
Month = 30.4375 days. Monthly drug cost = 4-week price × 30.4375 ÷ 28. Total budgets round up whole packs. Unknown prices are not treated as within budget.
6 / 6 options shown
tirzepatide
injection · Once weekly
12 month budget ₩7,700,000
12 month plan ₩7,700,000
Observed · 5 mg
바라봄피부과 · 2026년 7월 게시 가격
Checked 2026-09-28
One clinic quote, not a national average. Fixed-dose budget, not an initiation/titration course.
Packs = ceil(months × 30.4375 / supply days). Total = packs × quote + entered additional visits.
semaglutide
injection · Once weekly
12 month budget ₩7,700,000
12 month plan ₩7,700,000
Observed · 2.4 mg
바라봄피부과 · 2026년 7월 게시 가격
Checked 2026-09-28
One clinic quote, not a national average. Fixed-dose budget, not an initiation/titration course.
Packs = ceil(months × 30.4375 / supply days). Total = packs × quote + entered additional visits.
liraglutide
injection · Once daily
12 month budget Price unavailable
12 month plan Price unavailable
Unknown · Quote needed
No verified local quote. Your input is not a verified market price.
Packs = ceil(months × 30.4375 / supply days). Total = packs × quote + entered additional visits.
naltrexone + bupropion
oral · Twice daily (maintenance)
12 month budget Price unavailable
12 month plan Price unavailable
Unknown · Quote needed
No verified local quote. Your input is not a verified market price.
Packs = ceil(months × 30.4375 / supply days). Total = packs × quote + entered additional visits.
phentermine + topiramate
oral · Once daily
12 month budget Price unavailable
12 month plan Price unavailable
Unknown · Quote needed
No verified local quote. Your input is not a verified market price.
Packs = ceil(months × 30.4375 / supply days). Total = packs × quote + entered additional visits.
orlistat
oral · With fat-containing main meals, up to 3 daily
12 month budget Price unavailable
12 month plan Price unavailable
Unknown · Quote needed
No verified local quote. Your input is not a verified market price.
Packs = ceil(months × 30.4375 / supply days). Total = packs × quote + entered additional visits.
This table is wider than the screen; swipe sideways for the other columns.
| Product | 3 mo | 6 mo | 12 mo | 18 mo | 24 mo |
|---|---|---|---|---|---|
| Mounjaro | ₩2,200,000 | ₩3,850,000 | ₩7,700,000 | ₩11,000,000 | ₩14,850,000 |
| Wegovy injection | ₩2,200,000 | ₩3,850,000 | ₩7,700,000 | ₩11,000,000 | ₩14,850,000 |
| Saxenda | Price unavailable | Price unavailable | Price unavailable | Price unavailable | Price unavailable |
| Contrave | Price unavailable | Price unavailable | Price unavailable | Price unavailable | Price unavailable |
| Qsymia | Price unavailable | Price unavailable | Price unavailable | Price unavailable | Price unavailable |
| Xenical | Price unavailable | Price unavailable | Price unavailable | Price unavailable | Price unavailable |
Different values are shaded. Trial populations and durations differ; do not read them as an efficacy ranking.
| Dimension | Mounjaro | Wegovy injection |
|---|---|---|
| Ingredient | tirzepatide | semaglutide |
| Route / frequency | injection / Once weekly | injection / Once weekly |
| Normalized monthly drug cost | ₩597,879 | ₩597,879 |
| 3 month budget | ₩2,200,000 | ₩2,200,000 |
| 6 month budget | ₩3,850,000 | ₩3,850,000 |
| 12 month budget | ₩7,700,000 | ₩7,700,000 |
| 18 month budget | ₩11,000,000 | ₩11,000,000 |
| 24 month budget | ₩14,850,000 | ₩14,850,000 |
| Initial / maintenance dose | 2.5 mg / 5 / 10 / 15 mg (local label) | 0.25 mg / 2.4 mg (KR) |
| Label schedule (reference) | Korean label: 2.5 mg weekly for 4 weeks, then 5 mg. Further 2.5 mg increments at intervals of at least 4 weeks are clinician-directed, maximum 15 mg. Not a personal schedule. | Korean leaflet: weekly 0.25, 0.5, 1.0 and 1.7 mg for 4 weeks each, then 2.4 mg. Tolerability and changes require a clinician. |
| Trial / duration | SURMOUNT-1 / 72 weeks | STEP 1 / 68 weeks |
| Trial mean (not head-to-head) | 15% / 5 mg weekly | 14.9% / 2.4 mg weekly |
| Responder | ≥5% loss: 85% (5 mg arm) | ≥5% / ≥10% / ≥15%: 86.4% / 69.1% / 50.5% |
| KR / published prices | ₩550,000 / 28d / 5 mg / private clinic | ₩550,000 / 28d / 2.4 mg / private clinic |
| JP / published prices | Unknown | ¥52,000 / 28d / 2.4 mg / private clinic |
| US / published prices | Unknown | $349.00 / 28d / 2.4 mg / cash; $1,349.02 / 28d / 2.4 mg / list |
| UK / published prices | £180.00 / 28d / 5 mg / public / insurance | Unknown |
| Price evidence | Observed | Observed |
These are user assumptions, not offers from a clinic or card issuer. No discounts or refunds assumed. Equal-payment installments finance drug costs only; visits remain monthly. Stopping treatment does not erase financing obligations.
Finance cost ₩0 · Peak payment ₩1,100,000
Average across payment period ₩641,667 · 12 months
Budget / target ratio: ₩513,333 / kg · ₩513,333 / 1%
This table is wider than the screen; swipe sideways for the other columns.
| Month | Product / quote dose | Drug | Visits | Payment | Cumulative |
|---|---|---|---|---|---|
| 1 | Mounjaro / 5 mg | ₩1,100,000 | ₩0 | ₩1,100,000 | ₩1,100,000 |
| 2 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩1,650,000 |
| 3 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩2,200,000 |
| 4 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩2,750,000 |
| 5 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩3,300,000 |
| 6 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩3,850,000 |
| 7 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩4,400,000 |
| 8 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩4,950,000 |
| 9 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩5,500,000 |
| 10 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩6,050,000 |
| 11 | Mounjaro / 5 mg | ₩550,000 | ₩0 | ₩550,000 | ₩6,600,000 |
| 12 | Mounjaro / 5 mg | ₩1,100,000 | ₩0 | ₩1,100,000 | ₩7,700,000 |
Installment = principal × r / (1 − (1+r)^−n), r = APR / 1200; zero interest = principal / n. Only display values are rounded. Purchases begin on day zero; packs may leave unused stock.
Direct evidence / HIGH (trial endpoint only)
A trial endpoint does not identify when an individual reaches a goal. Fast/slow paths, incremental exercise effects and intermediate target dates lack evidence here. Confidence intervals around a group mean are not individual trajectories.
SURMOUNT-1 · 72 weeks · 15% mean loss · 5 mg weekly
Month of target attainment / total cost to reach target: insufficient evidence. Use the horizon selector for 12-, 18- or 24-month budgets.
This is a user-entered budget checkpoint, not an attainment forecast. Future cost difference is neither guaranteed savings nor advice to stop.
6m · Drug ₩3,850,000 + Visits ₩0 = ₩3,850,000
Difference in later purchase budget (before financing/prepayment) ₩3,850,000
These are source-specific observations, not national averages or universally available offers. Prices are not converted without an explicit exchange rate.
One clinic quote, not a national average. Fixed-dose budget, not an initiation/titration course.
바라봄피부과 · 2026년 7월 게시 가격
Checked 2026-09-28
One clinic quote, not a national average. Fixed-dose budget, not an initiation/titration course.
바라봄피부과 · 2026년 7월 게시 가격
Checked 2026-09-28
Restricted to established clinic patients; not a tourist purchase offer.
Hongo Masago Heart Clinic · private price table
Checked 2026-09-28
Public tariff effective September 2025; current individual quote unavailable
NHSBSA · reimbursement tariff, September 2025
Checked 2026-09-28
NovoCare eligibility/terms apply. Initial two-fill promotion excluded; program can change. No long-term price guarantee.
NovoCare · US list and conditional self-pay prices
Checked 2026-09-28
Not out-of-pocket cost; not comparable to cash price.
NovoCare · US list and conditional self-pay prices
Checked 2026-09-28
Enter matching monthly quotes for the same product, dose and visit inclusions. The listed Japanese clinic restricts access to established patients; it is not a travel purchase quote.
Enter total round-trip costs; explicitly enter zero for absent items. Assumes one trip; add repeat visits and FX fees to Other.
Enter both quotes, FX/date and every travel cost to calculate.
This does not recommend purchasing or importing medicine. Confirm local prescribing, medicine import rules and storage requirements with the relevant authorities and clinician.
Manufacturer → local subsidiary → distributor → clinic/pharmacy → consumer
| Metric | Current evidence |
|---|---|
| Price Premium | Insufficient like-for-like cost/substitute evidence |
| Unexplained Spread | Transfer prices/rebates undisclosed: cannot compute |
| Excess Margin Risk | Manufacturing/distribution costs unknown: not assessed |
| Investigation Priority | Verify dose, price type, date and inclusions first |
Local systems, negotiated discounts, patents, regulation and clinical services may contribute to price differences. Public data here cannot quantify each contribution or establish excess profit.
Review date 2026-09-28 · Posted prices are not verified transactions. Price and clinical confidence are separate.
US official materials now list oral Wegovy and 7.2 mg HD. Korean approval/sales were not verified, so they are not mixed into the six Korean comparison products. Korean liraglutide generics and actual efpeglenatide launch remain unverified.
한국릴리 · 마운자로 FAQ / 국내 공급 용량
Checked 2026-09-28
한국릴리 · 국내 허가 적응증
Checked 2026-09-28
SURMOUNT-1 · NEJM 2022
Checked 2026-09-28
Novo Nordisk Korea · 제품정보
Checked 2026-09-28
Novo Nordisk Korea · 위고비 환자용 설명서
Checked 2026-09-28
STEP 1 · NEJM 2021
Checked 2026-09-28
Novo Nordisk Korea · 제품정보
Checked 2026-09-28
Saxenda · US prescribing information
Checked 2026-09-28
SCALE · NEJM 2015
Checked 2026-09-28
광동제약 · 콘트라브 국내 발매 (2016)
Checked 2026-09-28
FDA · Contrave label (2025)
Checked 2026-09-28
Trial / n / baseline / response / dropout / time-course: Not verified
삼성서울병원 약제부 · 큐시미아 원내 도입
Checked 2026-09-28
Qsymia · US prescribing information
Checked 2026-09-28
CONQUER · Lancet 2011
Checked 2026-09-28
종근당 · 제니칼 제품 / 허가정보
Checked 2026-09-28
Trial / n / baseline / response / dropout / time-course: Not verified
NovoMedLink · US pen and oral Wegovy dosing
Checked 2026-09-28
한미약품 · 에페글레나타이드 출시 계획 (2026-06-18)
Checked 2026-09-28
Health insurance pays part of the cost under defined conditions.
Not covered by the health insurer; prices can vary by provider.
The amount you pay after insurance.
A drug price; distinguish reimbursement tariff from actual purchase cost.
The price charged to the next participant in the supply chain.
What was actually paid, with discounts and extras accounted for.
A self-pay price without insurance, not necessarily paid with physical cash.
Medicine taken by mouth.
Medicine delivered by injection.
Once every seven days. Four weeks is shorter than a calendar month.
Taken or administered once each day.
The amount of medicine per administration or day.
A clinician-directed increase in dose over time.
The ongoing dose after initiation; individual plans can differ.
The approved condition and population for a medicine.
The substance producing the medicinal action.
A later approved medicine with the same active ingredient.
The originally developed medicine or brand family.
A study of treatment effects and safety in people under defined conditions.
Average weight change in a trial; not a promise about your outcome.
A participant meeting a predefined weight-loss threshold.
The condition at the start of a study or observation.
Weight in kg divided by height in metres squared; not a prescription decision.
The proportion of body weight that is fat; not used to predict response here.
A price before discounts or rebates.
A public tariff, not necessarily what a patient pays.
A price observed at a particular provider and time; not a national average.
All costs added up from the start to a given time.
Total cost divided by the number of months in the same comparison period.
Budget divided by target kg lost; not a guaranteed price of achieving that loss.
Budget divided by target percentage points lost; a planning ratio.
A scenario where costs are paid in one payment.
Payments spread over time; consider the total financing cost.
Installments with zero interest; availability must be confirmed with the provider.
Money paid before a service; check cancellation and refund terms.
Price ranges requiring a defined sample; not invented when data are absent.
An official source; an official tariff is not necessarily a patient price.
An observation cross-checked against additional evidence.
Observed in a posting; an actual transaction has not been verified.
A calculated value based on stated assumptions.
A user report, not established fact without independent verification.
Unverified or missing data. It does not mean zero cost.
Uncertainty around a group estimate, not a range of individual outcomes.
Report a different price. Do not include names, contact details, patient IDs, prescriptions, diagnoses or body measurements.
Saved through the existing AMS private feedback service. Public aggregates require reviewed reports sharing country, product, dose, supply unit and consultation inclusion.
Raw reports stay private. Report volume alone never earns HIGH confidence.
No. AMS compares budgets and public evidence; it does not prescribe or rank efficacy.
A trial average cannot establish an individual trajectory. A planned budget is different from a treatment outcome.
There are currently no affiliate links. Affiliate status is excluded from sorting; non-affiliate options receive equal treatment.
